COMPARING THE POTENTIAL BUDGET IMPACT OF NOVEL THERAPIES FOR ADVANCED MELANOMA IN SECOND-LINE UNDER BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Tsuchiya, C. T. [1 ]
Buschinelli, C. T. [1 ]
Tobaruella, F. S. [1 ]
Maximo, M. F. M. [1 ]
Guzzo, M. R. [1 ]
Goncalves, T. M. [1 ]
机构：
[1] Roche Brazil, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.2021
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A683 / A683
页数：1
相关论文
共 47 条
  • [1] ESTIMATING THE POTENTIAL BUDGET IMPACT OF ZELBORAF (VEMURAFENIB) FOR ADVANCED MELANOMA TREATMENT IN BRAZILIAN PRIVATE HEALTH CARE SYSTEM
    Tsuchiya, C. T.
    Buschinelli, C. T.
    Maximo, M. F. M.
    Tobaruella, F. S.
    Borges, L. G.
    VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
  • [2] Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective
    Klein, Robert W.
    Kabadi, Shaum
    Cinfio, Frank N.
    Bly, Christopher A.
    Taylor, Douglas C. A.
    Szymanski, Keith A.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (08) : 807 - 816
  • [3] ANALYSIS OF ORCHAMENTAL IMPACT OF AXITINIBE ON THE SECOND LINE OF CARCINOMA TREATMENT OF METASTATIC RENAISSANCE CELLS UNDER PERSPECTIVE OF THE BRAZILIAN HEALTH PRIVATE SYSTEM
    Alexandre, R. F.
    Squiassi, H. B.
    Santana, C. F.
    VALUE IN HEALTH, 2017, 20 (09) : A872 - A873
  • [4] Budget impact of the incorporation of second-line drug treatment for diabetic macular edema in the Brazilian Unified National Health System from the perspective of the Minas Gerais State Health Department, Brazil
    Izidoro, Jans Bastos
    Piazza, Thais
    Gurgel Andrade, Eli Iola
    Alvares-Teodoro, Juliana
    CADERNOS DE SAUDE PUBLICA, 2019, 35 (08):
  • [5] BUDGET-IMPACT ANALYSIS OF THE INTRODUCTION OF REGORAFENIB IN BRAZILIAN SUPPLEMENTARY HEALTHCARE SYSTEM AS A SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH SORAFENIB
    Bergamelli Ramos, N.
    Palhares, R.
    Yamamoto, L.
    Paladini, L.
    Pegoretti Rosa, B.
    Nardi, E. P.
    Saad, R.
    VALUE IN HEALTH, 2019, 22 : S77 - S77
  • [6] ESTIMATING THE BUDGET IMPACT OF ADDING AVASTIN (BEVACIZUMAB) TO FRONT LINE TREATMENT FOR ADVANCED OVARIAN CANCER IN BRAZILIAN SUPPLEMENTARY HEALTH CARE SYSTEM
    Tsuchiya, C. T.
    Buschinelli, C. T.
    Maximo, M. F. M.
    Tobaruella, F. S.
    Goncalves, T. M.
    VALUE IN HEALTH, 2013, 16 (07) : A400 - A400
  • [7] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF VISCOSUPPLEMENTATION WITH ORTHOVISC™ (HYALURONAN) IN KNEE OSTEOARTHRITIS, FROM THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
    Rezende, M. U.
    Hernandez, A. J.
    Namba, M. M.
    Fernandes, R. A.
    Takemoto, M. L. S.
    Santos, P. M. L.
    Repsold, D. M.
    Silva, R. C.
    Andrade, P. C.
    VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
  • [8] A FIVE YEARS BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF ADALIMUMAB FOR CROHN'S DISEASE PATIENTS FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM
    Menezes, F. G.
    Chibana, V
    VALUE IN HEALTH, 2015, 18 (07) : A663 - A663
  • [9] METASTATIC BREAST CANCER TREATMENT PATTERNS AND COSTS OF OUTPATIENT CARE UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
    Teich, V
    Teich, N.
    Nita, M.
    Donato, B. M.
    Rached, R.
    Rahal, E.
    VALUE IN HEALTH, 2009, 12 (07) : A493 - A494
  • [10] AFLIBERCEPT FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A BUDGET IMPACT ANALYSIS UNDER THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTH CARE SYSTEM
    Oliveira, L. E.
    Caires, A. L.
    Abreu, G. R.
    Nita, M. E.
    VALUE IN HEALTH, 2017, 20 (05) : A156 - A156
12345